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Despite several advances in the understanding of ovarian cancer pathobiology, in terms of
driver genetic alterations in high-grade serous cancer, histologic heterogeneity of epithe-
lial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer
is disappointingly low when compared to that of breast or prostate cancer. One of the
factors contributing to the poor survival rate from ovarian cancer is the development of
chemotherapy resistance following several rounds of chemotherapy. Although unicellular
drug resistance mechanisms contribute to chemotherapy resistance, tumor microenvi-
ronment and the extracellular matrix (ECM), in particular, is emerging as a significant
determinant of a tumor’s response to chemotherapy. In this review, we discuss the poten-
tial role of the tumor microenvironment in ovarian cancer recurrence and resistance to
chemotherapy. Finally, we propose an alternative view of platinum-sensitive recurrence to
describe a potential role of the ECM in the process.
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The majority of patients with advanced ovarian cancer develop
recurrent disease within 3 years (1, 2) and die within 5 years
because relapsed disease is almost always incurable (3). Although
initial recurrences are frequently platinum-sensitive, patients
eventually develop resistance to platinum-based chemotherapy
(3). Accordingly, resistance to chemotherapy, whether intrinsic
(primary) or acquired (secondary) resistance, is a major prob-
lem in the treatment of ovarian cancer and the main contributing
factor in cancer-associated mortality.
The initial response to platinum-based chemotherapy in ovar-
ian cancer can be broadly classified into three groups: platinum-
refractory, platinum-resistant, and platinum-responsive. These
classifications are based mainly on clinical evidence and useful
in the clinical management of ovarian cancer. Among them, the
platinum-refractory group is perhaps the easiest to conceptualize
because these patients do not respond to platinum-based therapy
and show progression during the course of the therapy. On the
other hand, platinum resistance is defined by less than 6 months
of remission following chemotherapy (3). Clinically, these patients
will show initial response to chemotherapy but experience relapse
within 6 months of the last round of chemotherapy, a time course
often described as platinum-free interval or treatment-free inter-
val. Treatment-free interval less than 6 months is often used as
a clinical cutoff to define platinum-resistant disease because of
empirical evidence (4). For patients who initially respond to
platinum-based therapy, there is a spectrum of response that lasts
from a little over 6 months to several years.
Although several genomic studies have been conducted to
identify the underlying genetic basis of this tumor behavior in
response to chemotherapy, major mechanisms or biological path-
ways that contribute to differential response to chemotherapy are
not fully understood. It is generally accepted that multiple molec-
ular mechanisms contribute to chemotherapy resistance and that
a single mechanism is unlikely to account for tumor response to
chemotherapy.
Recent review by Galluzzi et al. provides an excellent concep-
tual view of tumor intrinsic mechanisms associated with cisplatin
resistance (5). Alterations in pre-targets (associated with drug
metabolism and transport before it reaches to its intracellular
targets), on-targets (associated with DNA damage signaling and
repair),post-targets (associated with apoptosis and survival signal-
ing), and off-targets (components not directly affected by cisplatin
but counteract the lethal effect of cisplatin) are associated with cis-
platin resistance (5). Although cisplatin-resistant mechanisms are
well studied and reviewed, molecular mechanisms associated with
platinum-sensitive recurrence is not well understood.
An interesting aspect of ovarian cancer is that the majority of
patients who relapse long after chemotherapy can be rechallenged
with the same chemotherapy (4). These patients are described as
having platinum-sensitive recurrence. Therefore, the traditional
view of intratumor heterogeneity and the clonal selection of resis-
tant cancer cells by chemotherapy does not fit well with the
clinical evidence because the selection of resistant cells from het-
erogeneous tumor cell population following chemotherapy would
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have resulted in platinum-resistant recurrence and not platinum-
sensitive recurrence. Platinum-sensitive recurrent ovarian cancer
is a subject of numerous research and clinical studies because the
majority of ovarian cancer patients fall into this category (2, 6).
From a research point of view, platinum-sensitive recurrence is
an enigma. In a traditional viewpoint, platinum-resistant or -
refractory ovarian cancer can be explained by a simple model
in which intrinsically resistant tumor cells from heterogeneous
tumor population were selected for by chemotherapy resulting in
emergence of chemotherapy-resistant or -refractory tumors (7,
8) (Figures 1A,B). It is difficult to apply this simplistic model to
platinum-sensitive recurrent disease because not all tumor cells
that persist through initial rounds of chemotherapy become resis-
tant to chemotherapy. In fact, provided that patients experience
long remission prior to relapse, these patients will likely respond
to platinum-based chemotherapy again.
CANCER STEM CELLS AS A MECHANISM OF
PLATINUM-SENSITIVE RECURRENCE
With the emergence of cancer stem cell hypothesis, platinum-
sensitive recurrence could be explained by putative cancer stem
cells. Agarwal and Kaye proposed that in patients with platinum-
sensitive recurrence, heterogeneous chemo-naïve tumor may con-
tain clonal population of chemotherapy-sensitive tumor cells,
quiescent, or dormant tumor cells that are resistant to chemother-
apy, and chemotherapy-resistant tumor cells (Figures 1C,D).
The last two groups of tumor cells may constitute a small pro-
portion in the tumor. Therefore, upon treatment, the bulk of
tumor will respond to chemotherapy, and patient will experience
long remission. However, upon the completion of chemotherapy,
the last two populations of cells persist as residual tumor cells,
and they begin to regrow and repopulate the tumor, resulting
in recurrence (Figures 1C,D). In this model, quiescent or dor-
mant tumor cells that persist after chemotherapy repopulate the
tumor with rapidly proliferating chemotherapy-sensitive tumor
cells, thus leading to platinum-sensitive recurrence. This model
is supported by the observation of increased density of post-
chemotherapy residual tumors having increased cancer stem cells,
but recurrences remote from treatment having similar densities
of cancer stem cells as the primary tumor (9). With subsequent
rounds of platinum-based chemotherapy, the initially small frac-
tion of intrinsically resistant, non-quiescent tumor cells continue
to expand, thus leading to eventual platinum resistance. In this
model, putative tumor stem cells fit the role of chemotherapy-
resistant, quiescent tumor cells that persist after chemotherapy and
repopulate the tumor with differentiated, chemotherapy-sensitive
tumor cells. Several studies indicate the presence of putative can-
cer stem cells in ovarian cancer, thus supporting the plausibil-
ity of tumor stem cells in platinum-sensitive recurrent ovarian
cancer (10, 11).
TUMOR DORMANCY AS A MECHANISM OF
PLATINUM-SENSITIVE RECURRENCE
In addition to putative cancer stem cells that exist as quiescent,
dormant, or intrinsically resistant tumor cells that persist through
chemotherapy and repopulate the tumor after chemotherapy,
some tumor cells may enter dormancy due to specific tumor
microenvironment. It is suggested that cancer cells in transit and
cancer cells in unfavorable microenvironment (such as hypoxia,
nutrient stress, and lack of growth factors) may enter dormancy
(12). For example, Kreso et al. studies indicate that dormant
cells in colorectal cancer persist through chemotherapy though
they retain potent tumor initiating potential (13). Therefore, after
non-quiescent tumor cells are eliminated by chemotherapy and
when favorable microenvironment is restored, these dormant cells
have the potential to repopulate the tumor (13). In addition,
recent studies have shed more light into autophagy as a player
in inducing tumor dormancy. Elegant studies by Lu et al. (14),
showed that although the tumor suppressor geneARHI promoted
autophagy-induced cell death in vitro, factors from the tumor
microenvironment switchedARHI -induced autophagy to a tumor
survival mechanism and caused tumor dormancy in vivo. There-
fore, autophagy and tumor dormancy may constitute another
mechanism by which tumor cells persist through chemotherapy
and repopulate the tumor upon completion of chemotherapy,
thereby resulting in recurrence. Interestingly,Lu et al also show that
the inhibition of tumor microenvironment-induced autophagy
with the autophagy inhibitor chloroquine results in cell death
(14), and therefore autophagy may be therapeutically exploited
to minimize tumor dormancy and enhance therapeutic effect of
conventional chemotherapy.
MATRIX-DEPENDENT CHEMOTHERAPY RESISTANCE AS A
POSSIBLE MECHANISM OF PLATINUM-SENSITIVE
RECURRENCE
Here, we propose an alternate hypothesis for platinum-sensitive
recurrence. In this view point, we propose that cancer cells can
acquire extracellular matrix (ECM)-dependent platinum resis-
tance (15). These matrix-associated cells persist after chemother-
apy and repopulate the tumor after chemotherapy, resulting in
recurrence (Figure 1E). Implicit in this hypothetical model is that
these cancer cells are not intrinsically resistant to platinum-based
therapy. Rather, they are resistant to chemotherapy due to their
contact with particular components of ECM. Therefore, tumor
repopulated by these persistent residual cells is likely to be sen-
sitive to chemotherapy again if repopulated tumor cells are not
in contact with the right components of ECM, thereby resulting
in platinum sensitivity. It is important to note that our proposed
model represents an alternative hypothesis that seeks to comple-
ment and not substitute previous hypothetical models involving
tumor stem cells or cancer dormancy. In fact, our proposed hypo-
thetical model may be related to tumor stem cells and cancer
dormancy. It is suggested that tumor stem cells exist in particular
niche (16, 17) and that specific components of ECM are involved
in the establishment of stem cell niche (18). Therefore, it is con-
ceivable that ECM, through its role in the maintenance of stem cell
properties, may contribute to chemotherapy resistance. In addi-
tion,ECM has been shown to modulate tumor dormancy and serve
as a “gatekeeper” in transition from quiescence to proliferation in
cancer cells (19). Therefore, it is conceivable that ECM, through its
regulation on tumor dormancy, may contribute to chemotherapy
resistance.
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FIGURE 1 | Proposed models of platinum-resistant and
platinum-sensitive recurrence. (A) Platinum-refractory tumor. In this model,
tumor consists mainly of chemotherapy-resistant cells. Upon treatment,
these resistant cells continue to expand thereby resulting in progression
during the treatment. (B) Platinum resistance. In this model, tumor consists
of a large proportion of chemotherapy-sensitive and a small proportion of
chemotherapy-resistant tumor cells. Upon treatment, chemotherapy-sensitive
cells are eliminated, resulting in measurable clinical response. However,
resistant tumor cells repopulate the tumor, and recurrence is observed within
6 months from the last chemotherapy. (C) A model of platinum-sensitive
recurrence. In this model, quiescence “cancer stem cells” persist following
chemotherapy, and repopulate the tumor after chemotherapy resulting in
recurrence. Because repopulated tumor is derived from “cancer stem cells,”
these tumor cells retain original phenotype in terms of their response to
chemotherapy. Therefore, these tumors are expected to be sensitive to
chemotherapy, thereby resulting in platinum-sensitive recurrence. (D) A
model of acquired platinum resistance. In this model, original tumor is
composed of heterogeneous population of tumor cells, consisting of a small
population of chemotherapy-resistant tumor cells (orange colored cells),
putative “cancer stem cells” (green colored cells), and
chemotherapy-sensitive tumor cells (blue colored cells). Upon treatment,
residual cells are composed of chemotherapy-resistant cells and cancer stem
cells. Based on the cancer stem cell models, putative cancer stem cells are
capable of re-initiating the tumor. Due to the high replicative potential of
transit-amplifying cells that are derived from cancer stem cells, these cells
may contribute the bulk of recurrent tumor. It is important to note that
chemotherapy-resistant tumor cells (orange colored cells) will continue to
expand and contribute to recurrence. However, due to the population
expansion dynamics, these resistant cells may constitute a small proportion
of tumor bulk. However, with subsequent rounds of chemotherapy, resistant
tumor cell population will continue to expand to a point where they become
the majority of tumor bulk. At this point, tumor will not display clinically
measurable response, leading to clinical classification of acquired platinum
resistance. (E) Alternative view of platinum-sensitive recurrence. In this
model, tumor bulk is composed of heterogeneous population of tumor cells.
Some tumor cells are associated with specific components of extracellular
matrix (ECM), and this interact protect the cells from chemotherapy. These
cells persist along with putative cancer stem cells, and both contribute to
platinum-sensitive recurrence. It is important to note that this model posits
that some tumor cells that grow out will lose their contact with particular
components of the ECM, and they will become sensitive to chemotherapy.
(F) Unified model of acquired resistance. In this model, the original tumor is
composed of heterogeneous population of tumor cells consisting of cancer
stem cells, quiescent or dormant tumor cells, chemotherapy-resistant cells,
and tumor cells that are or are not associated with particular components of
the ECM. Following chemotherapy, four types of tumor cells are posited to
persist: chemotherapy-resistant tumor cells, cancer stem cells, quiescent or
dormant tumor cells, and tumor cells associated with specific components of
the ECM. All four cell types contribute to recurrent disease. After several
rounds of chemotherapy, the model also posits the emergence of novel
clones (red colored cells, derived from cells associated with the matrix, from
dormant tumor cells, or from cancer stem cells) that acquired additional
genetic alterations that allow de novo resistance to chemotherapy. All these
cells may contribute to acquired resistance.
EVIDENCE SUPPORTING MATRIX-DEPENDENT
CHEMOTHERAPY RESISTANCE
This proposed model is based on previous studies by various
groups indicating that cancer cells grown on specific matrix
proteins acquire resistance to chemotherapy (20, 21). For example,
Pat Morin and his colleagues have shown that ovarian cancer cells
grown on collagen VI are resistant to cisplatin (20). Moreover,
cells grown on collagen VI are more resistant than cells grown
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on collagen III (20), suggesting that acquired resistance is con-
text specific. It is also interesting to note that the initial discovery
of the potential role of ECM protein in cisplatin resistance was
made from in vitro cell line models in which cisplatin-sensitive
cell lines were made resistant to cisplatin by exposing the cells
to increasing concentrations of cisplatin. Subsequent analysis of
gene expression between the cisplatin-sensitive cells and the iso-
genic cisplatin-resistant cells indicates higher level of collagen VI
expression in cancer cells that became resistant to cisplatin (20).
These results highlight the dynamic nature of cellular response to
cisplatin and suggest that chemotherapy treatment could affect the
composition of the ECM by modulating gene expression within
cancer cells as well as within stromal cells.
Recent studies that used gene expression profiling technologies
also point to a particular group of tumors with pronounced stro-
mal/mesenchymal gene signatures to have worse outcome com-
pared to non-stromal gene signature groups (22, 23). In particular,
Helleman et al. suggested that ECM signature is associated with
chemotherapy resistance (22). Pathway analysis of gene expres-
sion data from tumors with differential response to chemotherapy
showed enrichment of ECM signatures in tumors with chemother-
apy resistance. In addition, Bowtell and his colleagues showed that
two molecular subsets underlies platinum resistance in ovarian
cancer: in one subset, cyclin E amplification is associated with
platinum resistance, and in another subset without cyclin E ampli-
fication, enrichment of cell adhesion, and ECM pathways are
associated with platinum resistance (23).
Recently, our own analysis of three datasets [the Cancer
Genome Atlas Ovarian Cancer data set (24), Tothill et al. (25),
and Bonome et al. (26)] resulted in the identification of several
ECM proteins as candidate biomarkers for poor clinical outcomes
with respect to recurrence and overall survival (27). In particu-
lar, we identified ECM protein fibrillin-1 as a central node in ECM
network, and high levels of fibrillin-1 expression in primary tumor
are associated with early recurrence in platinum-sensitive ovarian
cancer (27). Moreover, another set of gene signature, that is iden-
tified from the same study to be associated with early recurrence
and early death, consists of nuclear signaling mediated by Fos and
Jun nuclear factors (27). These two factors are known to serve as
downstream mediators of ECM signaling mediated through inte-
grins (28). Collectively, these two sets of observations point to a
potentially significant role of ECM-cell interaction in tumor cell’s
response to chemotherapy. It is important to note that expres-
sion levels of fibrillin-1 are not associated with platinum-resistant
or -refractory ovarian cancer. Rather, it is associated with early
recurrence of platinum-sensitive ovarian cancer. Based on these
results, we propose a hypothetical model in which ECM, consisting
of fibrillin-1 and other components, confers contact-dependent
platinum resistance.
In this model, cancer cells not directly attached to specific com-
ponents of ECM are sensitive to platinum and are eliminated
during chemotherapy (Figure 1E). Cancer cells that are directly
attached to specific components of ECM (such as Fibrillin-1)
are resistant to chemotherapy and persist during chemotherapy.
These cells repopulate the tumor giving rise to recurrent ovar-
ian cancer. The amount of residual tumor cells that remain after
chemotherapy will be dependent on the amount of ECM, and
therefore determine the speed of recurrence. It is conceivable that
tumors with a larger component of ECM will have larger amount
of residual cells remaining after chemotherapy and quicker recur-
rence, whereas tumors with smaller component of ECM will have
smaller amount of residual cells remaining after chemotherapy
and slower recurrence. Results from our immunohistochemical
analysis of fibrillin-1 support this view (27). Although ECM com-
ponents in this model of acquired resistance are tumor extrinsic, it
should be noted that the levels of ECM component within tumor
microenvironment is a function of tumor intrinsic factors and host
intrinsic factors, and therefore intrinsic gene expression within
tumor cells may also contribute to differences in ECM deposition
and resistance.
A UNIFIED VIEW
In this unified hypothetical model, in patients with platinum-
refractory ovarian cancer, tumor contains intrinsically resis-
tant tumor cells; thus tumor cells are refractory to treatment
and progress through treatment (Figure 1A). In patients with
platinum-resistant ovarian cancer, i.e., those that recur within
6 months from the last round of chemotherapy, chemo-naïve
tumor initially contains heterogeneous populations of chemosen-
sitive as well as intrinsically resistant tumor cells. Upon treatment,
chemosensitive tumors were eliminated, thus producing partial
treatment response. However, intrinsically resistant tumor cells
persist and expand during the treatment, thus leading to early
recurrence (Figure 1B). Another scenario might exist whereby
these tumors contain a larger component of ECM, which allows a
larger component of residual cells to persist after chemotherapy,
thereby permitting quicker relapse. If this were true, these tumors
that recur within 6 months from the last round of chemother-
apy may still contain chemotherapy-sensitive cancer cells and
may respond to chemotherapy. In fact, an objective clinical
response can be obtained in small percentage of patients with less
than 6 months of platinum-free interval, the so called platinum-
resistant tumors. Finally, in the last component of the unified
hypothesis, patients with platinum-sensitive ovarian cancer are
expected to have heterogeneous populations of tumor cells, con-
sisting of putative cancer stem cells, dormant or quiescent tumor
cells, and tumor cells that are in contact with specific components
of ECM. All these cells are expected to persist after chemother-
apy and contribute to platinum-sensitive recurrence (Figure 1F).
Eventually, after several rounds of chemotherapy, these cells may
evolve to acquire additional genetic alterations leading to acquired
resistance. It is also possible that intrinsically resistant tumor cells
may exist as a small fraction of total initial tumor bulk. After mul-
tiple rounds of chemotherapy, their proportional representation
may increase to a point that they eventually dominate the tumor
behavior and produce a resistant phenotype.
If proven, the proposed model of matrix-dependent platinum
resistance and disease recurrence has several clinical implications.
First, although the majority of ovarian cancer cells are intrinsi-
cally sensitive to platinum-based chemotherapy, a small fraction
of tumor cells acquire matrix-dependent platinum resistance and
escape from chemotherapy, leading to recurrence. Second, it will
be important to understand the role of ECM components in
platinum resistance because enhanced understanding in this area
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will allow us to design rational therapeutic approaches to elim-
inate residual cancer cells and provide more durable treatment
options. Third, targeting the tumor microenvironment by dis-
rupting cell-matrix interactions may be more “druggable” than
targeting putative cancer stem cells because experimental com-
pounds are already available to disrupt cell-matrix interactions
(heparin, RGD peptides, integrin inhibitors, etc.) or block kinase
signaling initiated by cell-matrix interactions (inhibitors of FAK,
Src, PI3K, Akt, etc.). Therefore, small molecule inhibitors and
peptides that block upstream ECM signaling or downstream intra-
cellular signaling cascades initiated by ECM signaling should be
tested in conjunction with conventional chemotherapy.
Finally, recent studies by Muranen et al. described matrix-
dependent resistance to dual-specificity PI3K/mTOR inhibitor
BEZ235 and other PI3K or mTOR inhibitors, such as Rapamycin,
LY294002, GDC0941, and PIK-90, in ovarian cancer cell lines (29).
Therefore, ECM may promote resistance to a broad spectrum
of cancer drugs and targeting the ECM and tumor microen-
vironment may provide significant advances in improving the
therapeutic efficacy of conventional as well as emerging novel
therapeutics.
CONCLUSION
Tumors can be considered as developmental organs defined by
abnormal signaling within tumor cells and between tumor cells
and their microenvironment. Tumor microenvironment, con-
sisting of (1) cellular components characterized by tumor cells,
tumor-associated fibroblasts, immune cells, endothelial cells, and
other resident cells, (2) physical components characterized by
ECM, and (3) biochemical components characterized by oxy-
gen tension, inflammatory cytokines, chemokines, and growth
factors, have long been recognized as a critical determinant of
tumor behavior. For example, the activation of v-src by Rous sar-
coma virus in chick embryo did not produce abnormal growth
(30, 31), but when these viral infected tissues were removed from
the embryonic microenvironment, they produced a transformed
phenotype (32). Similarly,melanoma cells injected into the embry-
onic microenvironment are reprogramed to remain indolent
whereas those cells injected into other microenvironments are
capable of inducing abnormal growth (33, 34). Finally, ECM atten-
uates chemotherapy-induced cytotoxicity in several cancer cell
lines from various cancer types (20, 21) – a phenomenon referred
to as cell adhesion-mediated drug resistance (35, 36). These studies
and others indicate that tumor microenvironment can contribute
to tumor dormancy, tumor progression, angiogenesis, metastasis,
and chemotherapy resistance (15, 37).
Given the significance of the tumor microenvironment in regu-
lating tumor behavior and, in particular, a tumor cell’s response to
chemotherapy, it is important that future drug discovery efforts
should include strategies to disrupt cell-matrix interactions or
downstream signaling cascades to determine the extent to which
these approaches will synergize with conventional chemother-
apy to enhance the effectiveness and durability of conventional
chemotherapy. Synthetic lethal screens should be performed in
more appropriate cellular context, such as 3D culture or matrix-
coated cultures to identify drug target genes or drug candidates
that synergize conventional chemotherapy.
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